A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer

Medical Oncology

Volumn 22, Issue 3, 2005, Pages 281-290

  Han, Ji Youn ^a   Dae, Ho Lee ^a   Sung, Young Lee ^a   Chun, Gun Park ^a   Hae, Young Kim ^a   Kim, Eun A ^a   Sung, Min Yoon ^a   Hong, Gi Lee ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Cisplatin; Irinotecan; Small cell lung cancer

Indexed keywords

CISPLATIN; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ELECTROLYTE DISTURBANCE; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LUNG SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; DIARRHEA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS;

EID: 23844460242     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:3:281     Document Type: Article

References (18)

1. Kudoh S, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998; 16: 1068-1074.
2. Noda K, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
3. de Jonge MJ, et al. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol 2000; 18: 187-194.
4. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
5. Fukuda M, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 1996; 56: 789-793.
6. Ma J, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998; 41: 307-316.
7. Goldwasser F, Valenti M, Torres R, Kohn KW, Pommier Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 1996; 2: 687-693.
8. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989; 7: 916-922.
9. Takeda Y, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001; 92: 269-275.
10. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. Geneva, Switzerland, World Health Organization, 1979.
11. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1998; 10: 1-110.
12. Kaplan ES, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
13. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
14. Yoon SM, Lee HG, Chun JH, Choi IG, Han JY, Lee JS. Two cases of acute toxic hepatitis and renal failure after ingestion of the extract of elm bark in lung cancer patients. J Kor Int Med 2003; 65 (suppl 3) S826-831.
15. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
16. Kobayashi K, et al. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 1999; 3: 491-496.
17. Takasuna K, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-3757.
18. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.